1-ethoxy-1-(p-methoxyphenyl)-chloromethane | 35365-02-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-ethoxy-1-(p-methoxyphenyl)-chloromethane
• 英文别名: 1-[Chloro(ethoxy)methyl]-4-methoxybenzene
• CAS: 35365-02-7
• 化学式: C₁₀H₁₃ClO₂
• 分子量: 200.665
• InChiKey: JFXZALJHZVOWNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-ethoxy-1-(p-methoxyphenyl)-chloromethane 在 四氯化钛 、 三乙胺 、 lithium diisopropyl amide 作用下， 生成 2-exo-(4-methoxyphenyl)-6-exo-phenyl-3,7-dioxabicyclo<3.3.0>octa-8-one
  参考文献：
  名称：

  2,6-二芳基单环氧木酚的短立体定向合成

  摘要：

  2-（对甲氧基苯基）-6-苯基-3,7-二氧杂双环[3.3.0] octan-8-one（6）具有自然的立体化学，已经通过分子内醛醇缩合反应通过立体定向途径合成[[（5）→（6）]。

  DOI：

  10.1039/c39840000590
• 作为产物：
  描述：

  4-甲氧基苯甲醛二乙基缩醛 在 氯化亚砜 、 乙酰氯 作用下， 生成 1-ethoxy-1-(p-methoxyphenyl)-chloromethane
  参考文献：
  名称：

  Stevens, David R.; Till, Clive P.; Whiting, Donald A., Journal of the Chemical Society. Perkin transactions I, 1992, # 2, p. 185 - 190

  摘要：

  DOI：

文献信息

• A short stereospecific synthesis of a 2,6-diarylmonoepoxylignanolide
  作者：Clive P. Till、Donald A. Whiting

  DOI：10.1039/c39840000590

  日期：——

  The 2-(p-methoxyphenyl)-6-phenyl-3,7-dioxabicyclo[3.3.0] octan-8-one (6), with natural stereochemistry, has been synthesized by a stereospecific route using an intramolecular aldol reaction [(5)→(6)].

  2-（对甲氧基苯基）-6-苯基-3,7-二氧杂双环[3.3.0] octan-8-one（6）具有自然的立体化学，已经通过分子内醛醇缩合反应通过立体定向途径合成[[（5）→（6）]。
• Dimensiosolvatic Effects. IV. Topomerization in Alkyl<b><i>α</i></b>-Chlorobenzyl Ethers and Insights into Mechanisms of Their Thermolyses
  作者：Michinori Oki、Hiroshi Ikeda、Hiromichi Miyake、Hirohito Mishima、Shinji Toyota

  DOI：10.1246/bcsj.71.915

  日期：1998.4

  Rates of topomerization in α-chlorobenzyl ethyl ether and its p-methyl as well as p-methoxy derivatives were determined in various solvents by the dynamic NMR method. The topomerization process was deduced to be ionic because the rates are enhanced in polar solvents as well as by electron-donating substituents. Concentration dependence study of the topomerization in carbon tetrachloride revealed that the observed process is unimolecular; the rates are not affected by concentration of the substrate if the concentration is lower than 0.2 mol L−1. The rates of topomerization are smaller for solutions in bulky solvents than in small solvents, the effects being clear for compounds with electron-donating substituents. The key feature of the kinetic parameters is that the entropy of activation is large and negative for all the solvents examined. The reaction mechanisms are discussed on the basis of these data. The effects of the molecular size of the solvent, dimensiosolvatic effects, are attributed to the effectiveness of the solvation in the formation of ion pairs. The results show that thermolyses of alkyl α-chlorobenzyl ethers are much slower reactions than the ionization. The nature of the reaction is discussed.

  利用动态NMR方法，在不同溶剂中测定了α-氯苄基乙基醚及其对甲基和对甲氧基衍生物的异构化速率。推断异构化过程为离子型，因为在极性溶剂中以及电子供体取代基的存在下，异构化速率得到增强。通过在四氯化碳中对异构化的浓度依赖性研究揭示，观察到的过程是单分子的；如果底物浓度低于0.2 mol L−1，异构化速率不受浓度的影响。在大体积溶剂中溶液的异构化速率比在小体积溶剂中小，对于具有电子供体取代基的化合物，这种效应很明显。动力学参数的关键特征是，对于所有检测的溶剂，活化熵都是大且负值。基于这些数据讨论了反应机理。溶剂分子大小、溶剂维度效应的影响归因于离子对形成中的溶剂化效果。结果表明，烷基α-氯苄基醚的热分解反应比电离反应慢得多。讨论了反应的性质。
• Novel aminodicarboxylic acid derivatives having pharmaceutical properties
  申请人：Alonso-Alija Cristina

  公开号：US20060094769A1

  公开（公告）日：2006-05-04

  The invention relates to compounds of formulae (II), (IV), and (VI) as shown below, wherein the several variable groups are as defined in the specification and claims. Processes for making these materials, and methods for using them in the synthesis of compounds for treatment of cardiovascular disorders and fibrotic disorders are also disclosed.

  本发明涉及以下式子（II），（IV）和（VI）的化合物，其中各个变量基团如规范和要求中所定义。还公开了制备这些材料的过程以及将它们用于合成治疗心血管疾病和纤维化疾病的化合物的方法。
• NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES
  申请人：Alonso-Alija Cristina

  公开号：US20100317854A1

  公开（公告）日：2010-12-16

  The invention relates to compounds of formulae (II), (IV), and (VI) as shown below, wherein the several variable groups are as defined in the specification and claims. Processes for making these materials, and methods for using them in the synthesis of compounds for treatment of cardiovascular disorders and fibrotic disorders are also disclosed.

  本发明涉及以下式子的化合物（II），（IV）和（VI），其中各个变量组在规范和要求中定义。还公开了制备这些材料的过程，以及在合成用于治疗心血管疾病和纤维化疾病的化合物的方法。
• US7517896B2
  申请人：——

  公开号：US7517896B2

  公开（公告）日：2009-04-14